Tag: Anticoagulants

For patients hospitalized with COVID-19 who are not critically ill, therapeutic-dose anticoagulation is beneficial

Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use

Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels

For discharged patients without suspected or confirmed VTE or other indication for anticoagulation, panel suggests not using anticoagulants

Prophylactic-dose anticoagulation, but not treatment-dose anticoagulation, associated with lower 60-day mortality

CVST with thrombocytopenia reported after COVID-19 vaccine with adenoviral vector; management similar to heparin-induced thrombocytopenia

Among patients with a-fib and/or VTE, about one-third received ASA in addition to a DOAC with no clear indication for ASA

Lower 30-day mortality, no increase in serious bleeding events seen among COVID-19 inpatients receiving early prophylactic anticoagulation

Venous thromboembolism seen in 6.3 percent and major bleeding seen in 2.8 percent of critically ill COVID-19 patients

Interim results show improvement in primary end point of need for ventilation, other organ-supportive interventions